IL314751A - Dosage regimen and management for the treatment or prevention of Guillan-Barré syndrome using the anti-c5 antibody crovalimab - Google Patents

Dosage regimen and management for the treatment or prevention of Guillan-Barré syndrome using the anti-c5 antibody crovalimab

Info

Publication number
IL314751A
IL314751A IL314751A IL31475124A IL314751A IL 314751 A IL314751 A IL 314751A IL 314751 A IL314751 A IL 314751A IL 31475124 A IL31475124 A IL 31475124A IL 314751 A IL314751 A IL 314751A
Authority
IL
Israel
Prior art keywords
crovalimab
guillan
antibody
dosage
prevention
Prior art date
Application number
IL314751A
Other languages
English (en)
Hebrew (he)
Inventor
Simon Bertrand Marie Buatois
Kenji Shinomiya
Alexandre Antoine Bernard Sostelly
Antoine Paul Maxence Soubret
Keisuke Gotanda
Original Assignee
Hoffmann La Roche
Chugai Pharmaceutical Co Ltd
Simon Bertrand Marie Buatois
Kenji Shinomiya
Alexandre Antoine Bernard Sostelly
Antoine Paul Maxence Soubret
Keisuke Gotanda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Chugai Pharmaceutical Co Ltd, Simon Bertrand Marie Buatois, Kenji Shinomiya, Alexandre Antoine Bernard Sostelly, Antoine Paul Maxence Soubret, Keisuke Gotanda filed Critical Hoffmann La Roche
Publication of IL314751A publication Critical patent/IL314751A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL314751A 2022-04-04 2023-04-03 Dosage regimen and management for the treatment or prevention of Guillan-Barré syndrome using the anti-c5 antibody crovalimab IL314751A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22166585 2022-04-04
PCT/EP2023/058608 WO2023194273A1 (en) 2022-04-04 2023-04-03 Dosage and administration regimen for the treatment or prevention of guillan-barré syndrome by the use of the anti-c5 antibody crovalimab

Publications (1)

Publication Number Publication Date
IL314751A true IL314751A (en) 2024-10-01

Family

ID=81327202

Family Applications (1)

Application Number Title Priority Date Filing Date
IL314751A IL314751A (en) 2022-04-04 2023-04-03 Dosage regimen and management for the treatment or prevention of Guillan-Barré syndrome using the anti-c5 antibody crovalimab

Country Status (11)

Country Link
US (1) US20250236662A1 (https=)
EP (1) EP4504774A1 (https=)
JP (1) JP2025511382A (https=)
KR (1) KR20240168984A (https=)
CN (1) CN118974082A (https=)
AU (1) AU2023249891A1 (https=)
CA (1) CA3251880A1 (https=)
IL (1) IL314751A (https=)
MX (1) MX2024012073A (https=)
TW (1) TW202404632A (https=)
WO (1) WO2023194273A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9388235B2 (en) * 2006-09-05 2016-07-12 Alexion Pharmaceuticals, Inc. Methods and compositions for the treatment of antibody mediated neuropathies
BR112017011235A2 (pt) 2014-12-19 2018-02-06 Chugai Pharmaceutical Co Ltd anticorpos anti-c5 e métodos de uso
DK3658184T5 (da) * 2017-07-27 2024-08-26 Alexion Pharma Inc Højkoncentrerede anti-c5-antistofformuleringer
CR20220040A (es) * 2019-07-31 2022-03-02 Hoffmann La Roche Régimen de dosificación y administración para el tratamiento o prevención de enfermedades relacionadas con c5 mediante el uso del anticuerpo anti-c5 crovalimab

Also Published As

Publication number Publication date
MX2024012073A (es) 2024-11-08
CN118974082A (zh) 2024-11-15
WO2023194273A1 (en) 2023-10-12
US20250236662A1 (en) 2025-07-24
EP4504774A1 (en) 2025-02-12
CA3251880A1 (en) 2023-10-12
AU2023249891A1 (en) 2024-08-08
AU2023249891A9 (en) 2024-08-15
JP2025511382A (ja) 2025-04-15
TW202404632A (zh) 2024-02-01
KR20240168984A (ko) 2024-12-02

Similar Documents

Publication Publication Date Title
HUE067202T2 (hu) Anti-C5 antitestek dózisa és beadása atípusos hemolitikus urémiás szindróma (aHUS) kezelésére
WO2018013918A3 (en) Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
CR20220563A (es) Una composición farmacéutica que comprende un anticuerpo anti-c5 contra una enfermedad relacionada con c5 y un producto de la misma
NZ764953A (en) Use of a vegf antagonist to treat angiogenic eye disorders
JP2017160178A5 (https=)
RU2016151757A (ru) Антагонисты pdl-1 и pd-1 для лечения hpv-отрицательных форм рака
MY210523A (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
EA201490378A1 (ru) ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β
RU2017134443A (ru) Способ лечения с применением традипитанта
NZ712294A (en) Methods for treating crohn’s disease using an anti-il23 antibody
MX2020010119A (es) Anticuerpo anti-cd27, fragmento de union a antigeno del mismo y uso medico del mismo.
RU2015134422A (ru) Применение левоцитиризина и монтелукаста при лечении васкулита
RU2017116740A (ru) Комбинации для лечения рассеянного склероза
MX2021004120A (es) Regimen de dosificacion para antagonistas de tfpi.
MX2024005430A (es) Composiciones, formas farmaceuticas y metodos de anticuerpos anti-tau.
EP3991749A3 (en) A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody
IL314751A (en) Dosage regimen and management for the treatment or prevention of Guillan-Barré syndrome using the anti-c5 antibody crovalimab
IL288636A (en) Dosage regimen and management for the treatment or prevention of c5-related diseases using the anti-c5 antibody crobalimab
HK40117833A (en) Dosage and administration regimen for the treatment or prevention of guillan-barré syndrome by the use of the anti-c5 antibody crovalimab
HK40117245A (en) Dosage and administration regimen for the treatment or prevention of guillan-barré syndrome by the use of the anti-c5 antibody crovalimab
MX2024007749A (es) Formulaciones clinicas de anticuerpos anti-tigit.
CO2021014370A2 (es) Regímenes de dosificación para anticuerpos anti-vrs y composiciones que los incluyen
IL313962A (en) Dosage and administration regimen for the treatment or prevention of guillan-barré syndrome by the use of the anti-c5 antibody crovalimab
MX2018005876A (es) Regimen de dosificacion de plasminogeno para la cicatrizacion de heridas.
MX2023005072A (es) Bloqueo de cd47 y terapias combinadas de los mismos para reducir la inflamacion vascular.